Algol Diagnostics and 2curex have signed a distribution agreement

Algol Diagnostics and Danish 2cureX have signed a distribution agreement to commercialize IndiTreat® in Finland. Under the terms of the collaboration, Algol Diagnostics will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen. The contract is initially for three years.

“We are thrilled to welcome Algol Diagnostics as our partner in Finland. They are a very strong player in the diagnostic field and have a synergistic product portfolio, and we are confident that they will succeed in commercializing IndiTreat® in their country”, said Fernando Andreu, CEO of 2cureX. 

Johan Wulff, Managing Director of Algol Diagnostics, says that the company has systematically developed its pathology diagnostics portfolio towards automatization and digitalization, contributing to fast and accurate patient diagnosis.

“Adding innovative tests like IndiTreat® makes our product offering even better. Leveraging our strong relationships to hospitals in Finland, we want to take an active role in helping healthcare professionals in Finland provide more personalized care to cancer patients”, Wulff says.

Nordic Region, at the forefront of precision oncology

According to Jesper Floyd Kristiansen, VP Business Development at 2cureX, the Nordic countries have developed a strong ecosystem for precision oncology in the last years, including several initiatives to incorporate innovative diagnostic approaches. 

“With a direct presence in Scandinavia and the collaboration with Algol in Finland we think we are in a better position to be a relevant player in that ecosystem”, Kristiansen said.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient’s tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”). For more information about 2cureX visit

Read more from 2cureX’s press release.